| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,030,000 |
| Market
Cap: |
903.16(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.48 - $21.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
| Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
11 |
| Total Shares Sold |
261,204 |
293,400 |
293,400 |
298,772 |
| Total Sell Value |
$4,645,136 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
| Total People Sold |
5 |
5 |
5 |
5 |
| Total Sell Transactions |
9 |
11 |
11 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wigginton Jon Marc |
Sr VP Clinical Dev & CMO |
• – – |
2016-08-01 |
4 |
AS |
$30.78 |
$615,600 |
D/D |
(20,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Sr VP Clinical Dev & CMO |
• – – |
2016-08-01 |
4 |
OE |
$4.70 |
$94,000 |
D/D |
20,000 |
20,000 |
|
- |
|
| Wigginton Jon Marc |
Sr VP Clinical Dev & CMO |
• – – |
2016-07-01 |
4 |
AS |
$27.22 |
$136,100 |
D/D |
(5,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Sr VP Clinical Dev & CMO |
• – – |
2016-07-01 |
4 |
OE |
$4.70 |
$23,500 |
D/D |
5,000 |
5,000 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2016-07-01 |
4 |
AS |
$27.22 |
$242,857 |
D/D |
(8,922) |
1,923 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2016-07-01 |
4 |
OE |
$0.94 |
$8,387 |
D/D |
8,922 |
10,845 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2016-05-27 |
4 |
AS |
$25.00 |
$125,000 |
D/D |
(5,000) |
1,923 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2016-05-27 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
6,923 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2016-05-18 |
5 |
A |
$0.00 |
$0 |
I/I |
34,619 |
167,782 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2016-05-18 |
5 |
D |
$0.00 |
$0 |
D/D |
(34,619) |
53,265 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2016-05-17 |
5 |
A |
$0.00 |
$0 |
I/I |
79,898 |
167,782 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2016-05-17 |
5 |
D |
$0.00 |
$0 |
D/D |
(79,898) |
53,265 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2016-05-16 |
4 |
OE |
$0.94 |
$32,542 |
D/D |
34,619 |
167,782 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2016-05-11 |
4 |
OE |
$0.94 |
$75,104 |
D/D |
79,898 |
133,163 |
|
- |
|
| Saran Atul |
SVP & General Counsel |
• – – |
2016-04-28 |
4/A |
D |
$20.84 |
$38,804 |
D/D |
(1,862) |
18,848 |
|
- |
|
| Saran Atul |
SVP & General Counsel |
• – – |
2016-04-28 |
4 |
D |
$20.84 |
$36,053 |
D/D |
(1,730) |
18,980 |
|
- |
|
| Costa Paulo F |
Director |
– • – |
2016-03-03 |
4 |
B |
$17.20 |
$172,000 |
D/D |
10,000 |
59,435 |
2.39 |
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical Dev & CMO |
• – – |
2016-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2016-02-11 |
4 |
OE |
$0.94 |
$11,244 |
D/D |
11,962 |
95,595 |
|
- |
|
| Risser Eric Blasius |
SVP, Business Development |
• – – |
2016-02-08 |
4 |
OE |
$0.94 |
$2,350 |
D/D |
2,500 |
4,000 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2016-01-29 |
4 |
OE |
$0.94 |
$9,400 |
I/I |
10,000 |
100,331 |
|
- |
|
| Stein Kathryn E |
SVP, Product Dev. & Regulatory |
• – – |
2016-01-07 |
4 |
OE |
$0.71 |
$44,825 |
D/D |
52,350 |
95,555 |
|
- |
|
| Bonvini Ezio |
Senior VP, Research |
• – – |
2016-01-07 |
4 |
OE |
$0.94 |
$12,517 |
D/D |
13,316 |
83,633 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical |
• – – |
2016-01-04 |
4 |
AS |
$29.64 |
$296,400 |
D/D |
(10,000) |
0 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical |
• – – |
2016-01-04 |
4 |
OE |
$4.70 |
$47,000 |
D/D |
10,000 |
10,000 |
|
- |
|
286 Records found
|
|
Page 8 of 12 |
|
|
0.19 (1.32%) 
